Maria Hägg Olofsson

Inhibition of proteasome deubiquitinating activity as a new cancer therapy

Pádraig D’Arcy, Slavica Brnjic, Maria Hägg Olofsson et al. · Nature Medicine · 2011 · 497 citations · Full text

Life Sciences, Molecular Biology, Oncology +14

Induction of mitochondrial dysfunction as a strategy for targeting tumour cells in metabolically compromised microenvironments

Xiaonan Zhang, Mårten Fryknäs, E Hernlund et al. · Nature Communications · 2014 · 253 citations · Full text

Medicine, Cancer Biology, Oncology +17

Irreversible inhibition of cytosolic thioredoxin reductase 1 as a mechanistic basis for anticancer therapy

William C. Stafford, Xiaoxiao Peng, Maria Hägg Olofsson et al. · Science Translational Medicine · 2018 · 243 citations · Full text

Medicine, Oncology, Pharmacology +5

Cytokeratin-18 Is a Useful Serum Biomarker for Early Determination of Response of Breast Carcinomas to Chemotherapy

Maria Hägg Olofsson, Takayuki Ueno, Yang Pan et al. · Clinical Cancer Research · 2007 · 154 citations · Full text

Medicine, Oncology, Pharmacology +12

The proteasome deubiquitinase inhibitor VLX1570 shows selectivity for ubiquitin-specific protease-14 and induces apoptosis of multiple myeloma cells

Xin Wang, Magdalena Mazurkiewicz, Ellin‐Kristina Hillert et al. · Scientific Reports · 2016 · 152 citations · Full text

Life Sciences, Cancer Biology, Molecular Biology +15